论文部分内容阅读
目的:观察增生性糖尿病性视网膜病变(PDR)行玻璃体切除术(PPV)行前玻璃体内注射康柏西普的效果。方法:前瞻性随机病例对照研究。将重庆市开州区人民医院2018年1月至2018年12月109例PDR患者分随机为3组：A组，PPV术前不注射康柏西普；B组，术前3天玻璃体内注射康柏西普；C组，术前5天玻璃体内注射康柏西普。观察3组术后效果。结果:A组手术时间(72.70±22.36)分钟，长于B组的(58.60±21.59)分钟及C组的(60.12±15.37)分钟(n P<0.05)。B组、C组术后1个月、3个月黄斑中心区厚度、血清VEGF水平均低于A组，BCVA均优于A组(n P<0.05)。B组、C组术中出血、术后玻璃体积血发生率均低于A组(n P0.05)。n 结论:术前康柏西普玻璃体内注射能缩短PPV手术时间，减少术中出血及术后玻璃体积血的发生，且能改善患者黄斑水肿。术前3天或5天注射效果无明显不同。“,”Objective:To observe the efficacy of intravitreal injection of conbercept before pars plana vitrectomy(PPV) for the treatment of proliferative diabetic retinopathy (PDR).Methods:This was a prospective randomized case-control study. Total of 109 patients with PDR were randomly divided into 3 groups. Group A underwent PPV without injection of conbercept. Group B underwent intravitreal injection of conbercept at 3 days before PPV. Group C underwent intravitreal injection of conbercept at 5 days before PPV. The postoperative efficacy was observed.Results:The surgery time of group A [(72.70±22.36) min] was longer than that of both group B [(58.60±21.59) min] and group C [(60.12±15.37) min] (n P<0.05). Thickness of central macular and serum VEGF levels in group B and group C at 1 and 3 months after surgery were smaller and lower than those in group A, while the BCVA was better than that in group A (n P<0.05). The incidence rates of bleeding during surgery and vitreous hemorrhage after surgery in group B and group C were lower than those in group A (n P0.05).n Conclusion:Intravitreal injection of conbercept before PPV can shorten the duration of surgery, reduce intra-operative bleeding and postoperative vitreous hemorrhage, and ameliorate macular edema.There is no significant difference in the efficacy of conbercept injection between 3 days and 5 days before PPV.